IRadimed Corporation (NASDAQ: IRMD) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 50.82 | EPS (ttm) | 1.82 | Insider Own | 20.69% | Shs Outstand | 12.78M | Perf Week | 1.80% |
| Market Cap | 1.18B | Forward P/E | 38.46 | EPS next Y | 2.40 | Insider Trans | -3.93% | Shs Float | 8.33M | Perf Month | -5.65% |
| Enterprise Value | 1.12B | PEG | 4.36 | EPS next Q | 0.54 | Inst Own | - | Short Float | 8.48% | Perf Quarter | 6.64% |
| Income | 23.06M | P/S | 13.69 | EPS this Y | 16.48% | Inst Trans | - | Short Ratio | 5.24 | Perf Half Y | -2.16% |
| Sales | 86.34M | P/B | 11.62 | EPS next Y | 15.35% | ROA | 20.05% | Short Interest | 705.83K | Perf YTD | -4.91% |
| Book/sh | - | P/C | 43.57 | EPS next 5Y | 13.25% | ROE | 23.45% | 52W High | 106.93 -14.27% | Perf Year | 31.54% |
| Cash/sh | - | P/FCF | 47.43 | EPS past 3/5Y | 19.71% 73.91% | ROIC | 20.18% | 52W Low | 66.90 37.02% | Perf 3Y | 111.53% |
| Dividend Est. | 0.80 (0.87%) | EV/EBITDA | 36.11 | Sales past 3/5Y | 16.59% 21.29% | Gross Margin | 75.86% | Volatility | 3.36% 3.26% | Perf 5Y | 174.81% |
| Dividend TTM | 1.24 (1.35%) | EV/Sales | 13.01 | EPS Y/Y TTM | 19.33% | Oper. Margin | 31.92% | ATR (14) | 3.29 | Perf 10Y | 398.38% |
| Dividend Ex-Date | Aug 14, 2026 | Quick Ratio | 9.46 | Sales Y/Y TTM | 17.81% | Profit Margin | 26.70% | RSI (14) | 46.03 | Recom | 2.00 |
| Dividend Gr. 3/5Y | 5.67% - | Current Ratio | 9.46 | EPS Q/Q | -6.12% | SMA20 | -1.74% | Beta | 0.90 | Target Price | 120.00 |
| Payout | 68.66% | Debt/Eq | 0.00 | Sales Q/Q | 0.00% | SMA50 | -1.95% | Rel Volume | 0.64 | Prev Close | 92.49 |
| Employees | 166 | LT Debt/Eq | 0.03 | Earnings | Nov 02 | SMA200 | -1.53% | Avg Volume | 138.26K | Price | 91.67 |
| IPO Date | Jul 16, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 4.55% 0.57% | Net Debt/EBITDA | -1.90 | Volume | 88,199 | Change | -0.89% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-11-26 | Reiterated | Lake Street | $100 → $120 | |
| Feb-10-26 | Reiterated | Roth Capital | Buy | $98 → $120 |
| Nov-03-25 | Reiterated | Roth Capital | Buy | $90 → $98 |
| Nov-03-25 | Reiterated | Lake Street | $75 → $100 | |
| Oct-31-25 | Resumed | Roth Capital | Buy | $60 → $90 |
| Aug-02-24 | Reiterated | Roth Capital | Buy | $65 → $60 |
| Jun-17-24 | Reiterated | Loop Capital Markets | $60 | |
| Jul-31-17 | Upgrade | Roth Capital | Neutral → Buy | |
| Oct-05-16 | Downgrade | Roth Capital | Buy → Neutral |
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 86 | 84 | 73 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 21 | 19 | 17 | — | — | — | — | — | — | |
| Gross Profit | 65 | 64 | 56 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 35 | 35 | 32 | — | — | — | — | — | — | |
| Research and Development | 4 | 3 | 3 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | -1 | — | — | — | — | — | — | |
| Operating Income | 27 | 26 | 22 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 2 | 2 | 2 | — | — | — | — | — | — | |
| Net Income Before Taxes | 30 | 28 | 24 | — | — | — | — | — | — | |
| Income Taxes | 7 | 6 | 5 | — | — | — | — | — | — | |
| Consolidated Net Income | 23 | 22 | 19 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 23 | 22 | 19 | — | — | — | — | — | — | |
| Net Income | 23 | 22 | 19 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.82 | 1.77 | 1.52 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.82 | 1.77 | 1.52 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.79 | 1.75 | 1.50 | — | — | — | — | — | — | |
| EBITDA | 31 | 31 | 25 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 51.21 | 55.59 | 36.67 | — | — | — | — | — | — | |
| Price To Sales Ratio | 13.86 | 15.06 | 9.79 | — | — | — | — | — | — | |
| Gross Margin | 75.58 | 76.19 | 76.71 | — | — | — | — | — | — | |
| Operating Margin | 31.40 | 30.95 | 30.14 | — | — | — | — | — | — | |
| Net Margin | 26.74 | 26.19 | 26.03 | — | — | — | — | — | — | |
| Shares Outstanding | 13 | 13 | 13 | — | — | — | — | — | — | |
| Market Capitalization | 1,192 | 1,265 | 715 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| GLENN JOHN | CFO | Jun 20 '26 | Option Exercise | 0.00 | 5,796 | 0 | 14,256 | Jun 23 |
| Scharen-Guivel Hilda Frederique | Director | Jun 04 '26 | Sale | 95.00 | 3,000 | 285,000 | 5,598 | Jun 04 |
| Susi Roger E. | CEO, President, Chairman | Jun 01 '26 | Sale | 90.60 | 2,500 | 226,507 | 2,162,500 | Jun 02 |
| Susi Roger E. | CEO, President, Chairman | May 27 '26 | Sale | 91.95 | 2,500 | 229,878 | 2,165,000 | May 28 |
| Susi Roger E. | CEO, President, Chairman | May 26 '26 | Sale | 92.23 | 5,000 | 461,166 | 2,167,500 | May 28 |
| Susi Roger E. | CEO, President, Chairman | May 19 '26 | Sale | 87.88 | 2,500 | 219,694 | 2,172,500 | May 20 |
| Susi Roger E. | CEO, President, Chairman | May 18 '26 | Sale | 87.51 | 5,000 | 437,571 | 2,175,000 | May 20 |
| Susi Roger E. | CEO, President, Chairman | May 12 '26 | Sale | 83.92 | 4,411 | 370,183 | 2,180,000 | May 13 |
| Susi Roger E. | CEO, President, Chairman | May 11 '26 | Sale | 84.54 | 3,089 | 261,158 | 2,184,411 | May 13 |
| Susi Roger E. | CEO, President, Chairman | May 05 '26 | Sale | 85.74 | 3,750 | 321,529 | 2,187,500 | May 06 |
| Susi Roger E. | CEO, President, Chairman | May 04 '26 | Sale | 85.69 | 3,750 | 321,333 | 2,191,250 | May 06 |
| Susi Roger E. | CEO, President, Chairman | Apr 28 '26 | Sale | 86.23 | 3,750 | 323,364 | 2,195,000 | Apr 30 |
| Susi Roger E. | CEO, President, Chairman | Apr 27 '26 | Sale | 89.16 | 3,750 | 334,346 | 2,198,750 | Apr 30 |
| Susi Roger E. | CEO, President, Chairman | Apr 21 '26 | Sale | 90.94 | 2,500 | 227,345 | 2,202,500 | Apr 22 |
| Susi Roger E. | CEO, President, Chairman | Apr 20 '26 | Sale | 93.36 | 5,000 | 466,779 | 2,205,000 | Apr 22 |